Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cel-Sci Corp
(NY:
CVM
)
1.635
+0.155 (+10.47%)
Streaming Delayed Price
Updated: 11:33 AM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cel-Sci Corp
< Previous
1
2
3
Next >
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
April 19, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
March 08, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology
March 03, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
February 15, 2023
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2022 Financial Results and Clinical & Corporate Developments
December 28, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
November 22, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
October 17, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
September 12, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Issues Letter to Shareholders
September 07, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
August 19, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Third Quarter Fiscal 2022 Financial Results
August 15, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors
August 08, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Announces Reddit AMA with Geert Kersten
July 14, 2022
From
CEL-SCI Corporation
Via
Business Wire
TinyGemsBreaks – SRAX Inc. (NASDAQ: SRAX) Shares Replays of 2022 LD Micro Invitational Company Presentations
June 16, 2022
Via
Investor Brand Network
CEL-SCI Corporation to Present at LD Micro Invitational
June 08, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Presents Phase 3 Multikine Head & Neck Cancer Data at ASCO
June 07, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Publication of ASCO 2022 Abstracts
May 27, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports Second Quarter Fiscal 2022 Financial Results
May 16, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
April 22, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Reports First Quarter Fiscal 2022 Financial Results
February 14, 2022
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Reports Fiscal 2021 Financial Results and Clinical & Corporate Developments
December 22, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Completes Commercial-Scale Buildout of Multikine Manufacturing Facility
October 22, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation (NYSE:CVM) Investor Investigation over Potential Wrongdoing
September 07, 2021
San Diego, CA -- (SBWIRE) -- 09/07/2021 -- Certain directors of CEL-SCI Corporation are under investigation over potential breaches of fiduciary duties.
Via
SBWire
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
August 16, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation (NYSE:CVM) Shareholder Notice: Investigation over Possible Violations of Securities Laws
July 13, 2021
San Diego, CA -- (SBWIRE) -- 07/13/2021 -- CEL-SCI Corporation is under investigation concerning potential securities laws violations in connection with certain financial statements.
Via
SBWire
CEL-SCI Corporation Issues Letter to Shareholders
July 07, 2021
From
CEL-SCI Corporation
Via
Business Wire
Discussion of Results of CEL-SCI’s Phase 3 Trial Is Now Available
July 02, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI to Conduct Investor Call Regarding Phase 3 Results Following Annual Shareholder Meeting on July 1, 2021
June 30, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
June 28, 2021
From
CEL-SCI Corporation
Via
Business Wire
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
June 25, 2021
From
CEL-SCI Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.